Physician
Presbyterian Healthcare Services
Presbyterian Healthcare Services was paid $40.92M by Medicaid between Jan 2018 and Dec 2024, across 254 billing codes. Its largest line is 99284, emergency room visit (serious) — 19% of everything it billed.
33Billing provider infoPRESBYTERIAN HEALTHCARE SERVICES
ESPANOLA, NM 87532
ESPANOLA, NM 87532
33aNPI1154307593assigned 12/19/2005
33bProvider typeEmergency Medicine Physician
28Total paid$40.92M
24GClaims649,271
24DCodes billed254
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Medicine Physician providers in New Mexico
Rank by total paid#5 of 39
Median peer was paid$669K
This provider vs. median61×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 116,292 | $6.22M | |
| 2019 | 89,274 | $5.25M | |
| 2020 | 50,500 | $3.52M | |
| 2021 | 67,973 | $4.12M | |
| 2022 | 102,666 | $6.00M | |
| 2023 | 125,380 | $8.37M | |
| 2024incomplete | 97,186 | $7.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 47,926 | 45,906 | $7.79M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 54,811 | 51,202 | $7.33M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 25,529 | 24,293 | $5.78M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 4.0% | 12,219 | 11,750 | $1.65M |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 3.3% | 5,242 | 4,530 | $1.36M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 3,766 | 3,643 | $1.30M |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 2.6% | 4,415 | 3,941 | $1.06M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 4,571 | 4,329 | $775K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 6,900 | 6,578 | $661K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 11,337 | 9,771 | $626K |
| 87631 | 1.5% | 4,423 | 4,304 | $623K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.5% | 13,193 | 11,076 | $597K |
242 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.5% | 12,849 | $595K |
| 80053 | Comprehensive metabolic panel | 1.0% | 31,802 | $418K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.0% | 2,714 | $415K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 8,232 | $413K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,179 | $384K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,456 | $378K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,826 | $376K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,959 | $363K |
| G0378 | Hospital observation service, per hour | <1% | 774 | $350K |
| 73562 | <1% | 3,873 | $341K | |
| A0425 | Ground mileage, per statute mile | <1% | 5,198 | $325K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,026 | $294K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 32,938 | $269K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,700 | $241K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,754 | $218K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 955 | $202K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 589 | $195K |
| 73610 | <1% | 1,805 | $174K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 814 | $168K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,470 | $167K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,357 | $161K |
| 73030 | <1% | 2,129 | $161K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,465 | $160K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,767 | $124K |
| 81513 | <1% | 938 | $123K | |
| 73630 | <1% | 1,967 | $120K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,594 | $119K |
| 73110 | <1% | 1,587 | $116K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 752 | $105K |
| 84484 | <1% | 6,646 | $91K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,494 | $90K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 610 | $90K |
| 73130 | <1% | 1,238 | $89K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,396 | $85K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 254 | $84K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,056 | $80K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,761 | $78K |
| 81025 | <1% | 6,676 | $76K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 19,826 | $73K |
| 96376 | <1% | 2,383 | $72K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,977 | $71K |
| 83690 | <1% | 8,597 | $71K | |
| 81001 | <1% | 12,867 | $67K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,605 | $63K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 656 | $63K |
| 72100 | <1% | 779 | $62K | |
| A0998 | Ambulance response and treatment, no transport | <1% | 829 | $62K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 677 | $61K |
| 97161 | <1% | 1,707 | $61K | |
| 94726 | <1% | 666 | $60K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,268 | $60K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 818 | $58K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 814 | $56K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 822 | $55K |
| 82962 | <1% | 7,051 | $51K | |
| 94060 | <1% | 446 | $50K | |
| 87081 | <1% | 5,854 | $50K | |
| 87650 | <1% | 2,133 | $49K | |
| 83735 | <1% | 6,803 | $48K | |
| 94664 | <1% | 705 | $44K | |
| 73502 | <1% | 946 | $42K | |
| 84439 | <1% | 4,600 | $40K | |
| 76830 | Ultrasound, transvaginal | <1% | 447 | $39K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 139 | $39K |
| 95811 | <1% | 67 | $39K | |
| 87040 | <1% | 2,810 | $38K | |
| 83605 | <1% | 4,348 | $36K | |
| 10060 | <1% | 435 | $36K | |
| 83880 | <1% | 1,757 | $35K | |
| 94375 | <1% | 350 | $35K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,360 | $34K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 959 | $33K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 873 | $33K |
| 85027 | <1% | 5,123 | $33K | |
| J3490 | Unclassified drugs | <1% | 19,541 | $33K |
| 94729 | <1% | 684 | $32K | |
| 82077 | <1% | 2,650 | $30K | |
| 87481 | <1% | 936 | $29K | |
| 85379 | <1% | 1,612 | $28K | |
| 81514 | <1% | 116 | $28K | |
| 84702 | <1% | 1,523 | $28K | |
| 87077 | <1% | 3,087 | $28K | |
| 84703 | <1% | 2,114 | $27K | |
| 87186 | <1% | 2,241 | $27K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 304 | $26K |
| 86780 | <1% | 1,905 | $26K | |
| 71250 | <1% | 225 | $26K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 79 | $25K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,104 | $24K |
| 80061 | Lipid panel | <1% | 1,976 | $24K |
| 73080 | <1% | 352 | $24K | |
| 81003 | <1% | 5,524 | $23K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 41 | $22K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 233 | $22K |
| 85610 | <1% | 5,128 | $22K | |
| 86850 | <1% | 2,142 | $21K | |
| 82728 | <1% | 1,495 | $21K | |
| 59025 | Fetal non-stress test | <1% | 144 | $20K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 720 | $19K |
| 71101 | <1% | 233 | $19K | |
| 93971 | <1% | 269 | $18K | |
| 82805 | <1% | 348 | $18K | |
| 86803 | <1% | 1,227 | $17K | |
| 73120 | <1% | 163 | $16K | |
| 93976 | <1% | 144 | $15K | |
| 90715 | <1% | 988 | $13K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,674 | $13K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 979 | $13K |
| 87660 | <1% | 587 | $13K | |
| 87480 | <1% | 573 | $13K | |
| 87510 | <1% | 572 | $13K | |
| 97162 | <1% | 324 | $13K | |
| 86900 | <1% | 2,302 | $12K | |
| 82075 | <1% | 387 | $12K | |
| 96367 | <1% | 218 | $12K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 31 | $12K |
| 87653 | <1% | 289 | $11K | |
| 73090 | <1% | 159 | $11K | |
| 74019 | <1% | 114 | $10K | |
| 86901 | <1% | 2,300 | $10K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 331 | $10K |
| 76801 | <1% | 114 | $10K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 27 | $10K |
| 73140 | <1% | 163 | $10K | |
| 94618 | <1% | 133 | $10K | |
| 29125 | <1% | 89 | $9K | |
| 82607 | <1% | 682 | $9K | |
| Q3014 | Telehealth originating site facility fee | <1% | 263 | $9K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 151 | $9K |
| 86140 | <1% | 2,176 | $8K | |
| 20610 | <1% | 117 | $8K | |
| 83550 | <1% | 930 | $8K | |
| 87430 | <1% | 483 | $8K | |
| 82140 | <1% | 555 | $8K | |
| 82570 | <1% | 1,639 | $8K | |
| 12001 | <1% | 83 | $8K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,818 | $8K |
| 36000 | <1% | 1,198 | $8K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 38 | $7K |
| 73590 | <1% | 125 | $7K | |
| 80305 | <1% | 525 | $7K | |
| 82043 | <1% | 1,286 | $7K | |
| 83540 | <1% | 994 | $7K | |
| 80076 | <1% | 612 | $6K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,949 | $6K |
| 82746 | <1% | 472 | $6K | |
| 85652 | <1% | 1,307 | $6K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,608 | $6K |
| 87340 | <1% | 535 | $6K | |
| 12002 | <1% | 70 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,954 | $5K |
| 83655 | <1% | 367 | $5K | |
| 72040 | <1% | 74 | $5K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 12 | $5K |
| 97750 | <1% | 175 | $5K | |
| 87807 | <1% | 320 | $5K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 32 | $5K |
| 86762 | <1% | 338 | $5K | |
| 72110 | <1% | 66 | $5K | |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 209 | $5K |
| 70498 | <1% | 12 | $4K | |
| 70486 | <1% | 28 | $4K | |
| 87070 | <1% | 319 | $4K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 43 | $4K |
| 51702 | <1% | 53 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,320 | $3K |
| 70496 | <1% | 12 | $3K | |
| 80143 | <1% | 223 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,221 | $3K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 766 | $3K |
| 74018 | <1% | 57 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 117 | $3K |
| 94760 | <1% | 429 | $3K | |
| 80179 | <1% | 192 | $3K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 27 | $3K |
| 80074 | <1% | 52 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,224 | $3K |
| 82550 | <1% | 329 | $2K | |
| 85014 | <1% | 834 | $2K | |
| 85018 | <1% | 800 | $2K | |
| 85730 | <1% | 358 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,474 | $2K |
| 76770 | <1% | 30 | $2K | |
| 87205 | <1% | 320 | $2K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 16 | $2K |
| 73522 | <1% | 12 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 329 | $1K |
| 93970 | <1% | 13 | $1K | |
| 87210 | <1% | 184 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,028 | $1K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 81 | $986.97 |
| 73560 | <1% | 16 | $953.73 | |
| 36416 | <1% | 539 | $925.62 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 551 | $907.16 |
| 83525 | <1% | 72 | $896.86 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 599 | $865.78 |
| 86038 | <1% | 70 | $773.98 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 747 | $674.61 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 216 | $648.13 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 21 | $643.12 |
| 84481 | <1% | 27 | $533.98 | |
| 73552 | <1% | 14 | $529.26 | |
| 81002 | <1% | 148 | $521.90 | |
| 86787 | <1% | 38 | $497.01 | |
| 87075 | <1% | 38 | $476.07 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 56 | $455.10 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 815 | $446.21 |
| 87581 | <1% | 12 | $435.48 | |
| 87486 | <1% | 12 | $435.48 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 236 | $434.28 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 76 | $432.44 |
| 94761 | <1% | 27 | $428.32 | |
| 82010 | <1% | 55 | $377.37 | |
| 82950 | <1% | 68 | $342.37 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 16 | $314.58 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 51 | $312.47 |
| 82248 | <1% | 60 | $287.59 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 32 | $269.18 |
| 86431 | <1% | 41 | $246.90 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 128 | $219.37 |
| 82247 | <1% | 42 | $203.40 | |
| 90670 | <1% | 58 | $198.43 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 12 | $174.00 |
| G0008 | Administration of influenza virus vaccine | <1% | 115 | $145.51 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 193 | $143.46 |
| 90686 | <1% | 24 | $126.82 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 35 | $125.26 |
| S0028 | Injection, famotidine, 20 mg | <1% | 65 | $119.39 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 16 | $95.79 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 188 | $89.48 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 31 | $67.17 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 51 | $39.97 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 16 | $31.86 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 13 | $28.18 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 15 | $21.64 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 16 | $18.04 |
| J1815 | Injection, insulin, per 5 units | <1% | 56 | $17.65 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 15 | $15.00 |
| Q2039 | Influenza virus vaccine, not otherwise specified | <1% | 67 | $14.39 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 15 | $2.72 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 139 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 199 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGARCIA, ROBERT (VP REGIONAL OPERATIONS)
| Provider | Location | Paid |
|---|---|---|
| Presbyterian Healthcare Services | Carrizozo, NM | $1.11M |
| Restoration Medical Equipment & Supply Co. LLC | Laredo, TX | $562K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.